EP1664333A2 - Criblage a haut rendement et sensibilite elevee pour mesurer l'activite kinase du recepteur beta-adrenergique et pour determiner l'impact sur cette activite de substances a tester - Google Patents
Criblage a haut rendement et sensibilite elevee pour mesurer l'activite kinase du recepteur beta-adrenergique et pour determiner l'impact sur cette activite de substances a testerInfo
- Publication number
- EP1664333A2 EP1664333A2 EP04764711A EP04764711A EP1664333A2 EP 1664333 A2 EP1664333 A2 EP 1664333A2 EP 04764711 A EP04764711 A EP 04764711A EP 04764711 A EP04764711 A EP 04764711A EP 1664333 A2 EP1664333 A2 EP 1664333A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- protein kinase
- protein
- receptor
- antibody
- substrate molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000694 effects Effects 0.000 title claims abstract description 51
- 238000012360 testing method Methods 0.000 title claims description 21
- 239000000126 substance Substances 0.000 title claims description 12
- 102000011262 beta-Adrenergic Receptor Kinases Human genes 0.000 title description 5
- 108010037997 beta-Adrenergic Receptor Kinases Proteins 0.000 title description 5
- 238000012203 high throughput assay Methods 0.000 title description 2
- 230000035945 sensitivity Effects 0.000 title description 2
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 102
- 108060006633 protein kinase Proteins 0.000 claims abstract description 102
- 238000003556 assay Methods 0.000 claims abstract description 47
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims abstract description 38
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims abstract description 38
- 239000000758 substrate Substances 0.000 claims description 86
- 150000001875 compounds Chemical class 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 73
- 239000011324 bead Substances 0.000 claims description 45
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 22
- 108010056715 G-Protein-Coupled Receptor Kinase 2 Proteins 0.000 claims description 21
- 108010090804 Streptavidin Proteins 0.000 claims description 15
- 230000007423 decrease Effects 0.000 claims description 15
- 229960002685 biotin Drugs 0.000 claims description 14
- 235000020958 biotin Nutrition 0.000 claims description 14
- 239000011616 biotin Substances 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 108091033319 polynucleotide Proteins 0.000 claims description 13
- 239000002157 polynucleotide Substances 0.000 claims description 13
- 102000040430 polynucleotide Human genes 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 108091000080 Phosphotransferase Proteins 0.000 claims description 10
- 230000005670 electromagnetic radiation Effects 0.000 claims description 10
- 238000013537 high throughput screening Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 102000020233 phosphotransferase Human genes 0.000 claims description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 9
- 230000001800 adrenalinergic effect Effects 0.000 claims description 9
- 230000026731 phosphorylation Effects 0.000 claims description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 9
- 238000012546 transfer Methods 0.000 claims description 8
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims description 7
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- -1 aromatic carbon compound Chemical class 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 238000004364 calculation method Methods 0.000 claims description 4
- 230000003292 diminished effect Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 230000005284 excitation Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 230000003551 muscarinic effect Effects 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 102000004436 G-Protein-Coupled Receptor Kinase 2 Human genes 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 238000012440 amplified luminescent proximity homogeneous assay Methods 0.000 claims 1
- 238000002165 resonance energy transfer Methods 0.000 claims 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 22
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 15
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 238000003016 alphascreen Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 102100023734 G protein-coupled receptor kinase 4 Human genes 0.000 description 6
- 101000829481 Homo sapiens G protein-coupled receptor kinase 4 Proteins 0.000 description 6
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 6
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 102100037281 Beta-adrenergic receptor kinase 2 Human genes 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 108091006027 G proteins Proteins 0.000 description 3
- 102000030782 GTP binding Human genes 0.000 description 3
- 108091000058 GTP-Binding Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 description 2
- 102100023686 G protein-coupled receptor kinase 6 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000806653 Homo sapiens Beta-adrenergic receptor kinase 2 Proteins 0.000 description 2
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 description 2
- 101000829473 Homo sapiens G protein-coupled receptor kinase 6 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091005682 Receptor kinases Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 230000009141 biological interaction Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002889 sympathetic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 101100216435 Bos taurus GRK2 gene Proteins 0.000 description 1
- 101100015815 Bos taurus GRK5 gene Proteins 0.000 description 1
- 102100031174 C-C chemokine receptor type 10 Human genes 0.000 description 1
- 108010088144 CCR10 Receptors Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108091006089 DNA- and RNA-binding proteins Proteins 0.000 description 1
- 101100176456 Drosophila melanogaster Gprk2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 150000000918 Europium Chemical class 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091004242 G-Protein-Coupled Receptor Kinase 1 Proteins 0.000 description 1
- 108010056716 G-Protein-Coupled Receptor Kinase 3 Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108090000799 Rhodopsin kinases Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Definitions
- High-Throughput-Assay with high sensitivity for measuring of the activity of ⁇ - adrenergic receptor kinase and for determining the impact of test substances on such activity.
- the invention refers to a GPCR specific protein kinase assay by means of head linked substrate molecules.
- GPCRs G-protein-coupled receptors
- ⁇ -AR ?-adrenergic receptors
- Decreased cardiac activity is mediated by the cholinergic parasympathetic system working through muscarinic acetylcholine GPCRs.
- Cardiac ⁇ -AR consists of both the ⁇ -i and ⁇ subtypes, and in the human heart, as in most mammals, the ⁇ i is predominant.
- the two proteins are rather similar in protein sequence, though the ⁇ -i is significantly larger due to a larger N-terminal extracellular region and a larger C3 cytoplasmic loop.
- Trimeric G-proteins consist of an a, ⁇ and y subunit, each represented by several different genes in humans.
- GRK G Protein Specific Receptor Kinase
- GRK1 rhodopsin kinase
- GRK2 ⁇ -adrenergic receptor kinase-1
- GRK3 ⁇ - adrenergic receptor kinase-2
- GRK4 GRK5; and GRK6.
- GPRK1 and wj283.2 encode, respectively, Drosophila and Caenorhabditid elegans proteins with 62% and 51% homology to bovine GRK2. Similary, GPRK2 and f19c6.1 encode Drosophila and C. elegans proteins with 50-53% homology to bovine GRK5.
- the amino acid sequence similarity is 53-93%, with GRK1 and GRK2 being the most divergent.
- GRKs are most closely related to the PKC and cAMP-dependent protein kinase families (PKAs). Based on sequence and functional similarities, the GRK family has been divided into three subfamilies: (a] GRK1 , (b] GRK2 or ⁇ -adrenergic receptor kinase ( ⁇ -ARK); (GRK2 and GRK3), and (c] GRK4 (GRK4, GRK5, and GRK6). Members of the GRK2 subfamily share approximately 84% sequence similarity, and members of the GRK4 subfamily share approximately 70% sequence similarity.
- PKAs PKC and cAMP-dependent protein kinase families
- cardiac ⁇ -adrenergic receptors are stimulated by an increased release of catecholamines from the sympathetic nerves to maintain cardiac output and blood pressure.
- This increase in ⁇ -adrenergic receptor agonists leads to a downregulation of the receptor (and thus to a lower receptor density) and a receptor desensitization mediated by overexpression of ⁇ ARK.
- treatment with ⁇ ARK inhibitors may be of benefit for the preservation of myocardial ⁇ -adrenergic receptor signaling and may delay the development of heart failure after myocardial infarction.
- GPT-binding-protein-coupled receptor kinase 2 (GRC2) binds and phosphorylates tubulin, Eur. J. Biochem. 255, 363-368" an assay for GRK2 has been described by means of radioactively labeled substrate molecules.
- the AlphaScreen technology is widely used for testing of different types of enzymes.
- AlphaScreen Assays of different specificity are commercially available e.g. from
- AlphaScreen is a bead based non-radioactive Amplified Luminescent Proximity
- a photosensitizer in the Donor bead converts ambient oxygen to a more excited singlet state.
- the singlet state oxygen molecules diffuse across to react with a thioxene derivative in the Acceptor bead, generating chemiluminescence at 370 nm that further activates fluorophores contained in the same bead.
- the fluorophores subsequently emit light at 520-620 nm.
- AlphaScreen provides a highly versatile, sensitive, time-resolved, homogeneous and miniaturizable means to efficiently perform assay development and HTS resulting in higher throughput at lower costs.
- the lifetime of singlet oxygen in solution is about 4 ⁇ s which corresponds to a diffusion distance of approximately 200nm. Thus, a signal is only generated when donor and acceptor beads are in close proximity to each other.
- biotinylated CCR5 peptide (Seq. ID No. 1 ) is phosphorylated by the kinase.
- the phosphorylated serine is recognized by a specific antibody which, in turn, is bound to protein A coupled acceptor beads.
- the biotinylated N-terminus of the CCR5 peptide is coupled to streptavidin-coated donor heads.
- the assay of the invention in particular the test of ⁇ ARK activity by means of the AlphaScreen technology design is new. Compared to the state of the art determination of the ⁇ ARK activity is much more sensitive since the change of substrate phosphorylation is detectable within the nM-range. Furthermore the assay is homogenous which means that additional washing steps or immobilization of reactants are easily avoidable since the reaction is performed by means of solid phases. The assay is suitable for miniaturiarisation which allows the use in high throughput screening by laboratory robots. A further advantage is that the substrate does not need to be modified by covalent binding to fluorescence dyes.
- Method for detecting the phosphorylation of a substrate molecule by a protein kinase wherein a] at least one protein kinase is provided, b] at least one substrate molecule of the protein kinase of a] is provided, c] at least one donor component which is able to bind to the substrate molecule from b] and which emits a signal after the donor component was irradiated by a light source, d] at least one acceptor component which is able to recognize the substrate of b] in case it had been phosphorylated and which acceptor component is able to receive a signal in the form of an electromagnetic radiation is provided, e] the protein kinase from a], the substrate molecule from b], the donor component from c] and the acceptor component from d] are brought in contact, f] the mixture of e] is irradiated with a light source in such a way that the donor component of c] is excited, g] the electromagnetic radiation which is e
- a substrate molecule shall mean any chemical compound which is phosphorylatable by a protein kinase.
- a substrate molecule consists preferably of a peptide or a protein.
- a substrate molecule may consist of a G-Protein coupled Receptor or a member of a signaling cascade.
- a donor component is able by means of a donor compound to emit a signal after irradiation by a light source.
- the signal may consist of an electromagnetic radiation which is characterized by a specific wavelength or may consist of an atom or of a molecule or another type of output.
- An acceptor component is able to emit electromagnetic radiation upon having received the signal from the donor component.
- This electromagnetic radiation is characterized by its specific wavelength. It can be detected by means of an analysis apparatus as e.g. by a spectrometer.
- the substrate molecule can be linked to an antibody which is able to bind to the donor component or the donor component is linked to an antibody which is able to bind to the substrate molecule.
- the substrate molecule can be linked to a first antibody and the donor component can be linked to a second antibody wherein either the first antibody is able to bind to the second antibody or the second antibody is able to bind to the first antibody.
- the linking of a compound to one or several other compounds shall mean that the connection between these two compounds occurs permanently.
- the linking is realized e.g. by covalent chemical bondages, or electrostatic forces as mediated by ionized molecules or by other means.
- binding of a compound to one or several other compounds shall start from a non- binding stage, then continue to the contracting of the two compounds after finally forming a strong bondage between the said compounds.
- This bondage may be characterized by binding constants which are preferably within range of 5x10 "9 to 5 «10 " 7 M.
- the substrate component is linked to a biotin molecule and the donor component is linked to streptavidin or the substrate component is linked to streptavidin and the donor compound is linked to biotin.
- Biotin and streptavidin can bind to each other.
- Other chemical groups linked to the substrate component or donor component which are able to bind to each other comprise e.g. DNA and RNA binding proteins and the corresponding polynucleotide binding motifs.
- the Protein kinase is e.g. the beta-Adrenerge-Receptor-Kinasel or the G-Protein- Coupled-Receptor-Kinase2.
- the substrate can consist of a G-protein coupled Receptor or of the muscarinic Acetylcholine-Receptor or an adrenergic alpha 2 Receptor.
- the acceptor component is linked to at least one antibody which specifically binds to the substrate of b] in case this substrate had been phosphorylated.
- an antibody is e.g. the monoclonal antibody E11/19. Manufacturing of this antibody was described in "Pollak-Kapp. et al., J. Biol. Chem. (2003), 278, 2190-2198".
- the electromagnetic radiation which is emitted by the mixture according to g] of the method of the invention for detecting the phosphorylation of a substrate molecule can be fluorescence radiation.
- the electromagnetic radiation according to g] may be detected, for example, with the aid of a photomultiplier.
- the light source for irradiation of the mixture according to f] of the method of the invention for detecting the phosphorylation of a substrate molecule can be a laser or a lamp.
- the signal from the donor component to the acceptor component can be transferred preferably by emissionless energy transfer.
- This energy transfer can be a fluorescence resonance energy transfer.
- the at least one compound or group of compounds according to b] comprises a europium salt-containing compound and that the at least one compound or group of compounds according to c] (acceptor group) may comprise allophycocyanine (Grepin et al. (2000), Drug Discovery Today 5, 212).
- the donor and acceptor groups may be dyes suitable for emissionless energy transfer. It is furthermore possible to use all compounds known to the skilled worker which are suitable for emissionless energy transfer, in particular for fluorescence resonance energy transfer (see, for example, Pope et al. (1999), Drug Discovery Today 4, 350).
- the signal from the donor component to the acceptor component can be transferred via singlet oxygen.
- the donor component according to c] can comprise a compound which is able to convert triplet oxygen to singlet oxygen after excitation by a laser wherein the acceptor component according to d] comprises at least one first compound excitable by singlet oxygen and at least one second compound capable of absorbing in an emissionless manner and emitting in the form of fluorescence radiation the energy absorbed by the first compound.
- the singlet oxygen formed may diffuse from the donor group to the acceptor group and react with the chemiluminescent substances present there.
- the energy released in the process is transferred to the fluorophores which finally emit the energy in the form of fluorescence radiation which can be detected using a photomultiplier.
- a precondition for a detectable signal is the spatial proximity of donor and acceptor beads, since singlet oxygen is unstable and decays in aqueous solution. Therefore, the binding components to be used in this method are chosen in such a way that, when the binding event occurs, the distance between the donor and acceptor groups is preferably less than 200 nm.
- donor group and acceptor group localized on particles the particles preferably having an average diameter of between 150 and 250 nm, particularly preferably of approximately 200 nm.
- the preferred use of the particles here is such that the final concentration of acceptor group-carrying particles is 1-40 ⁇ g/ml and the final concentration of acceptor group-carrying particles is 1-80 /vg/ml.
- the binding capacity of the particles may be, for example, from approximately 0.1 nM to 1 nM per ⁇ m/ml particles.
- the donor group is excited by irradiating at a wavelength of 680 nm, using a laser, and the radiation emitted by the acceptor group can be detected at a wavelength between 520 and 600 nm. According, it is possible, in this case, for the method to be carried out in such a way that donor and acceptor beads carrying donor and acceptor groups are introduced initially.
- the donor and/or acceptor compound can consist of particles on which donor groups or acceptor groups are localized on. Such particles have preferably an average diameter of approximately 200 nm.
- the method of the invention for detecting the phosphorylation of a substrate molecule may further comprise in another embodiment the steps of adding at least one test substance and observing how the test substance influences the activity of the protein kinase.
- the method of the invention is in either case an HTS (high throughput screening)- capable method which may be carried out hom ⁇ genously in the form of a one-step method.
- the method of the invertion is carried out according to the "mix and measure" principle.
- the HTS-capable assay systems of the invention are used here preferably for carrying out the above-described methods of the invention.
- a particular characteristic feature of the methods of the invention is the possibility of monitoring the kinasing of the substrate in solution, since none of the reactants needs to be immobilized on a solid phase. Moreover, it is possible to measure the protein kinases from biological sources directly.
- Fluorescence is, in theory, the most sensitive analytical technique. As many intra- and intermolecular processes are able to modulate the label emission, it was therefore under consideration very early on as a technique of choice for designing homogeneous assays. Polarization, quenching, time correlation, lifetime variation as well as fluorescence resonance energy transfer (FRET) have been applied to probing molecular interactions. Among these techniques, FRET is of particular interest.
- the distance Ro (for which transfer is 50% efficient) lies within the 1-7 nm range. Taking advantage of these properties, FRET was used as a spectroscopic ruler to reveal proximity relationships in biological macromolecules.
- the invention comprises an assay for determining the activity of a G-Protein-Coupled-Receptor specific protein kinase wherein a] a protein kinase is provided, b] a donor bead, which streptavidin is linked to, of an amplified luminescent proximity homogenous assay is provided, c] a substrate molecule, which a biotin molecule is covalently linked to, of the protein kinase from a] is provided, which substrate molecule is phosphorylatable by the protein kinase from a], d] an antibody is provided that specifically recognises the phosphorylated substrate molecule from c] e] an acceptor bead, which is or can be linked to the antibody from d] by means of, e.g., protein A or a suitable secondary antibody, of an amplified luminescent proximity homogenous assay is provided, f] the protein kinase from a], the donor bead from b],
- the assay for determining the activity of a G-Protein- Coupled-Receptor specific kinase as mentioned before the protein kinase according to a] is selected from the group of ⁇ -Adrenergic-Receptor-Kinase 1 ( ⁇ ARK1] or G- Protein-Coupled-Receptor 2 (GRK2].
- the assay for determining the activity of a G-Protein- Coupled-Receptor specific kinase as mentioned before the substrate according to c] consists preferably of a G-Protein-Coupled-Receptor which is selected from the group of a muscarinic Acetylcholine-Receptor or an adrenergic alpha 2 Receptor.
- the assay for determining the activity of a G-Protein- Coupled-Receptor specific kinase as mentioned before the substrate according to c] consists preferably of a peptide being composed of between 10 and 50 amino acids or consists more preferably of a peptide being composed of an amino acid sequence of Seq. ID No. 1.
- the invention refers to a kit of parts, which kit of parts comprises a] at least one protein kinase, b] at least one donor bead, which streptavidin is linked to, of an amplified luminescent proximity homogenous assay, c] at least one substrate molecule, which a biotin molecule is covalently linked to, of a protein kinase from a] which substrate molecule is phosphorylatable by a protein kinase from a], d] an antibody is provided that specifically recognises the phosphorylated substrate molecule from c] e] at least one acceptor bead, which is or can be linked to the antibody from d] by means of, e.g., protein A or a suitable secondary antibody, of an amplified luminescent proximity homogenous assay is provided.
- kits of parts may be used simultaneously or one after another in one combined or several distinguished use forms.
- a use form consists for example of an incubation approach including a vessel for incubation, a liquid for incubation and incubation conditions as temperature or time.
- the protein kinase according to a] is selected from the group of ⁇ -Adrenergic-Receptor-Kinase1 ( ⁇ ARKI] or G-Protein-Coupled-Receptor-Kinase2 (GRK2].
- the substrate according to c] consists preferably of a G-Protein-Cou pas-Receptor or more preferably of a G- Protein-Coupled-Receptor which is selected from the group of a muscarinic Acetylcholine-Receptor or an adrenergic alpha2 Receptor.
- the substrate according to c] consists preferably of a peptide being composed of between 10 and 50 amino acids or consists more preferably of a peptide being composed of an amino acid sequence of Seq. ID No. 1.
- Such antibody can be linked to the acceptor bead via protein A or a suitable secondary antibody.
- the invention comprises the manufacturing of a kit of parts which kit of parts has been described as mentioned before wherein a] at least one protein kinase is provided, b] at least one donor bead, which streptavidin is linked to, of an amplified luminescent proximity homogenous assay is provided, c] at least one substrate molecule, which a biotin molecule is covalently linked to, of a protein kinase from a] which substrate molecule is phosphorylatable by a protein kinase from a], is provided, d] an antibody is provided that specifically recognises the phosphorylated substrate molecule from c] e] at least one acceptor bead, which is or can be linked to the antibody from d] by means of, e.g.,
- the kit of parts as described before can be used for determining the activity of a protein kinase and/or can be used in a screening process which may be organized as High-Throughput-Screening (HTS) for identifying a compound which increases the activity of a protein kinase and/or can be used for identifying a compound which decreases the activity of a protein kinase and/or can be used in a screening process which may be organized as High-Throughput-Screening (HTS] for identifying a compound which decreases the activity of a protein kinase.
- HTS High-Throughput-Screening
- the invention comprises a method for identifying a compound, which decreases the activity of a G-Protein-Coupled-Receptor specific protein kinase, wherein a] a protein kinase is provided, b] a donor bead, which streptavidin is linked to, of an amplified luminescent proximity homogenous assay is provided, c] a substrate molecule, which a biotin molecule is covalently linked to, of the protein kinase from a] is provided, which substrate molecule is phosphorylatable by the protein kinase from a] d] an antibody is provided that specifically recognises the phosphorylated substrate molecule from c] e] an acceptor bead, which is or can be linked to the antibody from d] by means of, e.g., protein A or a suitable secondary antibody, of an amplified luminescent proximity homogenous assay is provided, f] a chemical compound is provided, g] the protein is provided
- a method for identifying a compound which decreases the activity of a G-Protein-Coupled-Receptor specific protein kinase is selected from the group of ⁇ -Adrenergic-Receptor- Kinasel ( ⁇ ARKI] or G-Protein-Coupled-Receptor-Kinase2 (GRK2].
- a method for identifying a compound which decreases the activity of a G-Protein-Coupled-Receptor specific protein kinase as mentioned before the substrate according to c] consists preferably of a G-Protein-Coupled-Receptor or consists more preferably of a G-Protein-Coupled-Receptor which is selected from the group of a muscarinic Acetylcholine-Receptor or an adrenergic alpha 2-Receptor.
- a G-Protein-Coupled-Receptor specific protein kinase as mentioned before the substrate according to c] consists preferably of a peptide being composed of between 10 and 50 amino acids or consists more preferably of a peptide being composed of an amino acid sequence of Seq. ID No. 1.
- the monoclonal antibody E11/19 can be used.
- Such antibody can be linked to the acceptor bead via protein A or a suitable secondary antibody.
- the invention comprises a chemical compound having the ability to diminish the activity of a G-Protein-Coupled-Receptor specific kinase which is identified by a method for identifying a compound, which decreases the activity of a G- Protein-Coupled-Receptor as has been described in a former part of this invention.
- Such compound has preferably a mass of between 0,1 to 50 kDa.
- Such compound is preferably selected from one of the following groups of a protein, an amino acid, a polysaccharide, a sugar, a polynucleotide, a nucleotide, a fatty acid containing compound, a fat, a fatty acid, a derivative of a fatty acid and or an aromatic carbon compound.
- Such a compound could be the component of a medicament besides pharmaceutically acceptable expedients for the treatment of a disease which is linked to a disabled phosphorylation of a G-Protein-Coupled-Receptor.
- the invention comprises in one embodiment a peptide consisting of an amino acid sequence of Seq. ID No. 1.
- a peptide could be biotinylated.
- Synthesis of the peptide according to Seq. ID No. 1 carrying or lacking a Biotin-residue can be carried out by a peptide synthesis machine.
- Such synthesis machines are commercially available e.g. by Perkin Elmer.
- the peptide according to Seq. ID No. 1 carrying or lacking a Biotin residue can be used as substrate molecule in a protein kinase test.
- the invention concerns further the use of antibody E11/19 for detecting of a protein or peptide which is phosphorylated.
- This protein or peptide may encompass or consist of an amino acid according to Seq ID No. 1.
- Providing of a protein can be performed by a several step approach possibly including cloning of the corresponding gene of the protein in an appropriate expression vector, the transformation of e.g. bacterial cells, cultivation of such cells and expression of the said protein, harvesting of the cells from cultivation medium and the breakdown of the cells, and further isolation of the protein by e.g. ion exchange chromatography, size exclusion chromatography, high pressure liquid chromatography, affinity chromatography, polyacrylamide chromatography or other methods.
- the person skilled in the art will find appropriate methods for purification and handling of proteins in standard textbooks as in e.g. "Current Protocols in Protein Science - ISBN:0-471- 11184-8 (eds: John E. Coligan, Ben M. Duan, Hidde L. Ploegh, David W. Speicher, Paul T. Wingfield; Wiley Interscience 1995-2003)"
- Providing a cell includes the preparation, cultivation and further processing of the cell.
- Cells are provided, for example, by preparing suitable cell material from organs or tissues or by propagating suitable cell lines or microorganisms. Various suitable culture media can be used for cultivation. The cells are maintained at the optimum temperature for the organism. Where appropriate, preservatives, antibiotics, pH indicators, blood serum components, blood serum, auxiliaries or the other substances are added to the growth medium used in each case. Processes for preparation, cultivation and further processing are described in standard textbooks (Example: Basic Cell Culture; Ed. J.M. Davis; IRL Press; 1994).
- a construct to be expressed in a cell Such a construct consisting of a polynucleotide sequence can be prepared by a skilled worker in a routine manner with the aid of his specialist knowledge. The worker skilled in molecular biology / biochemistry can find the specialist knowledge for this, for example, in "F.M. Ausubel et al.; Current Protocols in Molecular Biology; John Willey & Sons; New York".
- a vector construct for example is prepared by incorporating a polynucleotide coding for the amino acid sequence of, for example, a GPCR into an expression vector.
- An expression vector is a vector in which a polynucleotide sequence can be translated in a host cell into a protein.
- Vectors may be derived from plasmids, viruses or cosmids and must be capable of autonomous replication. They generally contain an origin of replication, cleavage sites for restriction enzymes and marker genes such as, for example, antibiotic resistance genes.
- the polynucleotide sequence which is to be propagated or which has been introduced from the outside is under the functional control of a promoter.
- a promoter is a functional polynucleotide sequence of variable length, which is used to control transcription, i.e. synthesis of mRNA of a polynucleotide sequence immediately 3'- of said promoter.
- the recombinant vector construct comprises an expression vector usable in eucaryotes and/or procaryotes.
- An expression vector contains a promoter which can be linked functionally to a polynucleotide sequence so that a protein encoded by said polynucleotide sequence is synthesized in an organism, for example a bacterium, fungus or the cell of a eucaryotic cell line.
- the promoter may be inducible, e.g.
- Transfection is the introduction of foreign polynucleotide sequences into a host cell and the subsequent propagation of said polynucleotide sequence to any number of identical copies.
- a cell line is transiently transfected with a recombinant construct by means of routine methods which can be found by the skilled worker in the above mentioned textbook “Current Protocols in Molecular Biology, published by John Wiley & Sons, New York", or in “Sambrook et al.; A Laboratory Manual, Cold Spring Harbor Laboratory, ISBN 0- 87969-309-6". Examples of such routine methods are electroporation, Ca 2+ -phosphate coprecipitation and transfection by means of liposomes.
- the transfected genes may be expressed in the host cell by Western blotting of cell lysates of transfected cells in combination with an immunological detection method. For this too, the required laboratory protocols can be found by the skilled worker in the manuals mentioned above. Specific antibodies for immunodetection of different GPCR receptors are commercially available.
- a chemical compound is provided in particular by chemical synthesis or isolation of chemical substances from biological material.
- Suitable solvents may contain water, buffer substances (e.g. Tris, HEPES, MOPS, etc.], monovalent and/or divalent ions (e.g. K + , Na ⁇ Mg 2+ , Ca 2+ , etc.], acids (e.g. HCI, H 2 SO 4 , formic acid, acetic acid, etc.], bases (e.g. NaOH, etc.], alcohol (e.g. methanol, ethanol, glycerol], detergents (e.g. Na dodecyl sulfate, etc.], organic solvents (e.g. formamide, acetone, dimethyl sulfoxide, etc.] and other components, in particular solubilizers and stabilizers.
- buffer substances e.g. Tris, HEPES, MOPS, etc.
- monovalent and/or divalent ions e.g. K + , Na ⁇ Mg 2+ , Ca 2+ , etc.
- acids e.g. HCI, H 2 SO
- the skilled worker is able to bring in contact the components of the assay of the invention by using laboratory routine methods.
- Contacting may take place, for example, in Erlenmeyer vessels, tubes, Eppendorf vessels or in microtiter plates. Temperature-controlled incubators for which a constant temperature of, for example, 30°C or 37°C and fixed CO 2 or humidity conditions can be set may be used for said contacting. Contacting may in particular also be carried out in laboratory robot devices. Contacting is possible for different periods of time, from a few seconds to minutes and up to several hours. The conditions to be chosen in each case depend on the receptor, the cell line and the chemical compound.
- the final form of pharmaceutical relates to the final formulation, for example, as tablet, granules, spray, solution, ointment, tincture or other formulation forms.
- Processing to the final form refers to the preparation of the particular formulation in generally, the daily dose is in the range from 0.3 mg to 100 mg (typically from 3 mg to 50 mg) per day and per Kilogram of body weight, for example, 3-10 mg/kg/day.
- An intravenous dose may be, for example, in the range from 0.3 mg to 1.0 mg/kg and can most suitably be administered as infusion of from 10 ng to 100 ng per kilogram and per minute.
- Suitable infusion solutions for these purposes may contain, for example, from 0.1 ng to 10 mg, typically from 1 ng to 10 mg, per milliliter.
- Single doses may contain, for example, from 1 mg to 10 g of the active substance.
- ampoules for injections to contain, for example, from 1 mg to 100 mg
- single-dose formulations which can be administered orally such as, for example, tablets or capsules
- Detection solution anti-streptavidin antibody (1 :833], streptavidin donor beads (20 ⁇ g/ml], protein-A acceptor beads (40 ⁇ g/ml] in a buffer mixed from 1 part test buffer A containing the kinase, 2 test buffer A containing the kinase substrates and 2 parts test buffer B containing the phosphospecific antibody - 1 ⁇ l compound - + 5 ⁇ l detection solution - seal the plate, incubate overnight at room temperature - read the plate in the Alpha Quest
- Assay quality parameters were determined on the basis of high and low controls, which were run as internal standards on each assay plate. The following quality parameters are used as a measure to judge the suitability of an assay for high throughput screening.
- meanhigh control S/B mean ⁇ o control
- Table 1 Stock solutions
- Table 2 Buffers and reagents
- Fig. 1 Assay validation; ATP dependence; the apparent Km value was determined at 4 ⁇ M
- Fig. 2 Stability of the reaction mix; reagents are stable for more than 3 hours.
- Fig. 3 DMSO dependence of the assay; the assay tolerates up to 5% DMSO
- Fig. 4 Dose-response curve for heparin; the IC 50 was determined as 50 nM
- Fig. 5 Amino acid sequence according to Seq. Id No.1
- Fig. 6 Amino acid sequence including the ⁇ ARK-1 Sequence according to Seq. ID No. 2
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention se rapporte à un dosage qui permet de déterminer l'activité d'une protéine kinase spécifique du récepteur couplé à la protéine G, et ce à l'aide d'un dosage homogène de proximité par luminescence amplifié.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04764711A EP1664333A2 (fr) | 2003-09-11 | 2004-09-02 | Criblage a haut rendement et sensibilite elevee pour mesurer l'activite kinase du recepteur beta-adrenergique et pour determiner l'impact sur cette activite de substances a tester |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03020429A EP1514944A1 (fr) | 2003-09-11 | 2003-09-11 | Criblage à haut rendement et sensibilité élevée pour mesurer l'activité kinase du récepteur béta-adrénergique et pour déterminer l'impact sur cette activité de substances à tester |
EP04764711A EP1664333A2 (fr) | 2003-09-11 | 2004-09-02 | Criblage a haut rendement et sensibilite elevee pour mesurer l'activite kinase du recepteur beta-adrenergique et pour determiner l'impact sur cette activite de substances a tester |
PCT/EP2004/009751 WO2005024426A2 (fr) | 2003-09-11 | 2004-09-02 | Dosage haut debit a grande sensibilite permettant de mesurer l'activite d'une kinase specifique du recepteur $g(b)-adrenergique et de determiner l'influence de substances d'essai sur une telle activite |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1664333A2 true EP1664333A2 (fr) | 2006-06-07 |
Family
ID=34130177
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03020429A Withdrawn EP1514944A1 (fr) | 2003-09-11 | 2003-09-11 | Criblage à haut rendement et sensibilité élevée pour mesurer l'activité kinase du récepteur béta-adrénergique et pour déterminer l'impact sur cette activité de substances à tester |
EP04764711A Withdrawn EP1664333A2 (fr) | 2003-09-11 | 2004-09-02 | Criblage a haut rendement et sensibilite elevee pour mesurer l'activite kinase du recepteur beta-adrenergique et pour determiner l'impact sur cette activite de substances a tester |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03020429A Withdrawn EP1514944A1 (fr) | 2003-09-11 | 2003-09-11 | Criblage à haut rendement et sensibilité élevée pour mesurer l'activité kinase du récepteur béta-adrénergique et pour déterminer l'impact sur cette activité de substances à tester |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP1514944A1 (fr) |
WO (1) | WO2005024426A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2551670A1 (fr) * | 2011-07-27 | 2013-01-30 | Merck Patent GmbH | Analyse à base de cellules d'inhibiteurs de Nik |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030158387A1 (en) * | 1999-10-25 | 2003-08-21 | Wolf-Georg Forssman | Processed human chemokines PHC-1 and PHC-2 |
AU2001290965A1 (en) * | 2000-09-13 | 2002-03-26 | Archemix Corporation | Target activated nucleic acid biosensor and methods of using same |
-
2003
- 2003-09-11 EP EP03020429A patent/EP1514944A1/fr not_active Withdrawn
-
2004
- 2004-09-02 WO PCT/EP2004/009751 patent/WO2005024426A2/fr active Application Filing
- 2004-09-02 EP EP04764711A patent/EP1664333A2/fr not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2005024426A3 (fr) | 2005-09-01 |
WO2005024426A2 (fr) | 2005-03-17 |
EP1514944A1 (fr) | 2005-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chan et al. | Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit | |
Igishi et al. | Divergent Signaling Pathways Link Focal Adhesion Kinase to Mitogen-activated Protein Kinase Cascades: EVIDENCE FOR A ROLE OF PAXILLIN IN c-Jun NH2-TERMINAL KINASE ACTIVATION | |
Julien et al. | Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression | |
Chen et al. | RACK1 regulates specific functions of Gβγ | |
Gibbs et al. | Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor | |
US7279286B2 (en) | High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity | |
Endo et al. | Identification and characterization of zipper-interacting protein kinase as the unique vascular smooth muscle myosin phosphatase-associated kinase | |
Kennedy et al. | Selective disruption of the AKAP signaling complexes | |
US20090010911A1 (en) | Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities | |
CA2713276A1 (fr) | Determination de profil de selectivite de molecules interagissant avec la pi3k dirigees contre des cibles multiples | |
JP2013504302A (ja) | 阻害剤のスクリーニングのための、蛍光的p−ループ標識キナーゼの開発 | |
Kengyel et al. | Ankyrin domain of myosin 16 influences motor function and decreases protein phosphatase catalytic activity | |
Mahavadi et al. | Inhibition of MLC 20 phosphorylation downstream of Ca 2+ and RhoA: a novel mechanism involving phosphorylation of myosin phosphatase interacting protein (M-RIP) by PKG and stimulation of MLC phosphatase activity | |
Hübner et al. | Evidence for aggregation of protein kinase CK2 in the cell: a novel strategy for studying CK2 holoenzyme interaction by BRET 2 | |
Byrne et al. | Biochemical analysis of AKAP-anchored PKA signaling complexes | |
EP1514944A1 (fr) | Criblage à haut rendement et sensibilité élevée pour mesurer l'activité kinase du récepteur béta-adrénergique et pour déterminer l'impact sur cette activité de substances à tester | |
US7608407B2 (en) | Fluorescence polarization assay for determining histidine decarboxylase activity | |
US7097996B2 (en) | Methods of screening test compounds using GADD34L, an eIF2α-specific phosphatase subunit | |
RU2395813C2 (ru) | Применение биотинилированного полипептида для определения активности белок-фосфорилирующих ферментов | |
JP2011514148A (ja) | パーキンソン病の予防および処置用の候補化合物を同定するための熱変性スクリーニングアッセイ | |
Wang et al. | A self-scaffolding model for G protein signaling | |
EP1294929B1 (fr) | Methode permettant de detecter des modulateurs du domaine kinase du recepteur du vegf | |
Chen et al. | G protein β 1 γ 2 subunits purification and their interaction with adenylyl cyclase | |
US10254283B2 (en) | Biomarker for MELK activity and methods of using same | |
Reetoo | Purification of Protein Phosphatases and 14-3-3-binding Proteins and Their Regulation by the CAMP-PKA Pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060411 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20061128 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20111220 |